



NEHILIVE! PRESENTS . . .

NEXT GENERATION THERAPIES: WHAT'S NEXT?

Follow the conversation on Twitter using the hashtag #NEHILive




ABOUT NEHI

NEHI is a national nonprofit, nonpartisan organization composed of stakeholders from across **all key sectors of health and health care.**

Our mission: to advance innovations that improve health, enhance the quality of health care, and achieve greater value for the money spent.



“NEXT GENERATION” THERAPIES



More on the way:



- Gene Therapies
- Cell Therapies
- Immunotherapies
- Regenerative Medicine
- Other Advanced or Complex Treatments

Novel FDA approvals since 1993. Annual numbers of new molecular entities (NMEs) and biologics license applications (BLAs) approved by the Center for Drug Evaluation and Research (CDER).

Asher Mullard, “2018 FDA Drug Approvals,” *Nature Reviews-Drug Discovery*, January 2019

A POLICY MISMATCH

FDA Commissioner Scott Gottlieb (NEHI dinner, September 25, 2018)

“

The payoff from genomic research is now arriving, and the opportunities are monumental

”

But we have not yet figured out how to pay for many of the new therapies


NEHI Comments on the Trump Administration Drug Pricing Blueprint (July 16, 2018)

“

These therapies are likely to raise issues in pricing and payment that are very different from those raised by mature branded drugs or generics



NEHI WHITE PAPER (MARCH 2019)



FOR OUR LOCAL AUDIENCE

Mass. Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease

MARCH 20, 2018




FDA approves first drug to use RNA interference, based on discoveries made at UMass Medical School

Alnylam's patisiran will help patients with rare disease

UMass Medical School Communications

August 10, 2018

First CAR T-cell therapy approvals bolster booming immunotherapy market



PAYER CONCERNS

 Budget impact

 Impact on year-to-year insurance premiums

 “Real World” impact

 Durability of treatment

 Actuarial risk



The screenshot shows the top portion of a news article on the CommonWealth website. The header includes the site name 'CommonWealth' and navigation links for 'POLITICS', 'ECONOMY', 'ENVIRONMENT', 'EDUCATION', and 'CRIMINAL JUSTICE'. The article title is 'We need better tools to control pharma prices' by Marylou Sudders, dated Nov 7, 2018. The sub-headline reads: 'With many drug makers facing no competition, the market isn't working'. A 'SHARE' button is visible at the bottom left of the article preview.

DISCUSSION



MICHAEL SHERMAN, MD
Chief Medical Officer
SVP, Health Services
Harvard Pilgrim Health Care



CONSTANCE WILKINSON, JD
Board of Directors
Member of the Firm
Epstein Becker & Green, P.C.

Question & Answer Session

Please submit questions for panelists using the Q&A tool on the GoToWebinar dashboard.

If we can't get to your question during this session, we will email you with a response from the panelist(s).

THANKS FOR JOINING US

For more information, please contact:

Tom Hubbard

Vice President of Policy Research

NEHI

thubbard@nehi.net